# Safety and Preliminary Efficacy Study of EE001 in Health/Patients Adults with Mild, Moderate, or Severe (NYHA II-IV) Cardiac Insufficiency

> **NCT06884111** · EARLY_PHASE1 · COMPLETED · sponsor: **Anhui HygeianCells BioMedical Co., Ltd.** · enrollment: 6 (actual)

## Conditions studied

- Cardiac Insufficiency

## Interventions

- **DRUG:** EE001，70-105ml per day by IV

## Key facts

- **NCT ID:** NCT06884111
- **Lead sponsor:** Anhui HygeianCells BioMedical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-06-05
- **Primary completion:** 2024-12-11
- **Final completion:** 2024-12-11
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2025-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06884111

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06884111, "Safety and Preliminary Efficacy Study of EE001 in Health/Patients Adults with Mild, Moderate, or Severe (NYHA II-IV) Cardiac Insufficiency". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06884111. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*